Current approach to epithelial ovarian cancer based on the concept of cancer stem cells

Journal of B.U.ON.

Volumn 17, Issue 4, 2012, Pages 627-636

  Djordjevic, Biljana ^a   Stojanovic, S ^a   Conic, I ^b   Jankovic Velickovic, L ^a   Vukomanovic, P ^c   Zivadinovic, R ^c   Vukadinovic, M ^a  

^a UNIVERSITY OF NI   (Serbia)

^b Clinic of Oncology   (Iran)

^c CLINICAL CENTER NI   (Serbia)

Author keywords

Cancer stem cell; Chemoresistance; Epithelial ovarian cancer; Therapy

Indexed keywords

B RAF KINASE; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CD44V ANTIGEN; CISPLATIN; CYCLOPAMINE; ENDOGLIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA SECRETASE INHIBITOR; I KAPPA B; I KAPPA B KINASE BETA; K RAS PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; NESTIN; NOTCH1 RECEPTOR; NOTCH3 RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; PACLITAXEL; PROTEIN KINASE B BETA; PROTEIN P53; REACTIVE OXYGEN METABOLITE; STEM CELL FACTOR RECEPTOR; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 2; VISMODEGIB;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CANCER STAGING; CANCER STEM CELL; CANCER SURGERY; CELL DIFFERENTIATION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL RENEWAL; CYTOKINE PRODUCTION; DRUG EFFICACY; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; HISTONE MODIFICATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOLECULAR GENETICS; MULTICENTER STUDY (TOPIC); MUTAGENESIS; NONHUMAN; OVARY CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIDE POPULATION CELL; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

ANTIGENS, CD; FEMALE; GLYCOPROTEINS; HUMANS; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PEPTIDES; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84872415751     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009; 361: 170-177.
3. Heintz APM, Odicino F, Maisonneuve P et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95(Suppl 1):S161-S192.
4. Curley MD, Garrett LA, Schorge JO, Foster R, Rueda BR. Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. Front Biosci 2011; 16: 368-392.
5. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284. (Pubitemid 40488633)
6. Conic I, Dimov I, Tasic-Dimov D, Djordjevic B, Stefanovic V. Ovarian epithelial cancer stem cells. Sci World J 2011; 11: 1243-1269.
7. Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66: 9339-9344.
8. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737. (Pubitemid 27298715)
9. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 199; 367: 645-648.
10. Castor A, Nilsson L, Astrand-Grundstrom I et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 2005; 11: 630-637. (Pubitemid 40868303)
11. Cox CV, Evely RS, Oakhill A, Pamphilon DH, Goulden NJ, Blair A. Characterization of acute lymphoblastic leukemia progenitor cells. Blood 2004; 104: 2919-2925. (Pubitemid 39434980)
12. Cox CV, Martin HM, Kearns PR, Virgo P, Evely RS, Blair A. Characterization of a progenitor cell population in childhood Tcell acute lymphoblastic leukemia. Blood 2007; 109: 674-682. (Pubitemid 46105969)
13. Ishikawa F, Yoshida S, Saito Y et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bonemarrow endosteal region. Nat Biotechnol 2007; 25: 1315-1321. (Pubitemid 350076512)
14. Chan KS, Espinosa I, Chao M et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U SA2009; 106: 14016-14021.
15. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-3988. (Pubitemid 36418143)
16. Ponti D, Costa A, Zaffaroni N et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005; 65: 5506-5511. (Pubitemid 40911148)
17. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401. (Pubitemid 39551674)
18. Dalerba P, Dylla SJ, Park IK et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007; 104: 10158-10163. (Pubitemid 47175279)
19. O'Brien CA, Poliert A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110. (Pubitemid 46067310)
20. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-115. (Pubitemid 46067311)
21. Prince ME, Sivanandan R, Kaczorowski A et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007; 104: 973-978. (Pubitemid 46154721)
22. Hermann PC, Huber SL, Herrler T et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323. (Pubitemid 47355323)
23. Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.
24. Schatton T, Murphy GF, Frank NY et al. Identification of cells initiating human melanomas. Nature 2008; 451: 345-349.
25. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-10951. (Pubitemid 41713363)
26. Eramo A, Lotti F, Sette G et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15: 504-514. (Pubitemid 351267301)
27. Yang ZF, Ho DW, Hg MN et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008; 13: 153-166. (Pubitemid 351163165)
28. Suva ML, Riggi N, Stehle JC et al. Identification of cancer stem cells in Ewing's sarcoma. Cancer Res 2009; 69: 1776-1781.
29. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005; 65: 3025-3029. (Pubitemid 40524578)
30. Szotek P, Pieretti-Vanmarcke R, Masiakos P et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 2006; 103: 11154-11159. (Pubitemid 44156488)
31. Zhang S, Balch C, Chan MW et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68: 4311-4320.
32. Alvero AB, Chen R, Fu HH et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009; 8: 158-166.
33. Alvero AB, Fu HH, Holmberg J et al. Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells 2009; 27: 2405-2413.
34. Kusumbe AP, Mali AM, Bapat SA. CD 133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature. Stem Cells 2009;27:498-508.
35. Curley MD, Therrien VA, Cummings CL et al. CD 133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009; 27:2875-2883.
36. Hu L, McArthur C, Jaffe RB. Ovarian cancer stem-like sidepopulation cells are tumourigenic and chemoresistant. Br J Cancer 2010; 102:1276-1283.
37. Steffensen KD, Alvero AB, Yang Y et al. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J Oncol 2011; 2011: 620523.
38. Lee KR, Tavassol FA, Prat J et al. Tumours of the ovary and peritoneum. In: Tavassol FA, Devilee P (Eds): World Health Organisation classification of tumours, Pathology and genetics of the tumours of the breast and female genital organs. Lyon: Iarc Press, 2003,pp 117-145.
39. Chen VW, Ruiz B, Killeen JL, Cote TR, Wu XC, Correa CN. Pathology and classification of ovarian rumors. Cancer 2003; 97(10 Suppl): 2631-2642.
40. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004; 23:4144.
41. Landen CN Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; 26: 995-1005. (Pubitemid 351398093)
42. Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164: 1511-1518. (Pubitemid 38529752)
43. McMeekin DS, Burger RA, Manetta A, DiSaia P, Berman ML. Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis. Gynecol Oncol 1995; 59:81-86.
44. Yoshikawa H, Jimbo H, Okada S et al. Prevalence of endometriosis in ovarian cancer. Gynecol Obstet Invest 2000; 50 (Suppll): 11-17.
45. Erzen M, Rakar S, Klancnik B, Syrjanen K. Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol Oncol 2001; 83: 100-108. (Pubitemid 32959885)
46. Modesitt SC, Tortolero-Luna G, Robinson JB, Gershenson DM, Wolf JK. Ovarian and extraovarian endometriosis-associated cancer. Obstet Gynecol 2002; 100:788-795.
47. Stern RC, Dash R, Bentley RC, Snyder MJ, Haney AF, Robboy SJ. Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol 2001; 20: 133-139.
48. Sainz de la Cuesta R, Eichhorn JH, Rice LW, Fuller AF Jr, Nikrui N, Goff BA. Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol 1996; 60: 238-244. (Pubitemid 26058768)
49. Thomas EJ, Campbell IG. Molecular genetic defects in endo metriosis. Gynecol Obstet Invest 2000; 50 (Suppl 1): 44-50.
50. Wiegand KC, Shah SP, Al-Agha OM et al. ARID 1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532-1543.
51. Xu B, Hamada S, Kusuki I, Itoh R, Kitawaki J. Possible involvement of loss of heterozygosity in malignant transformation of ovarian endometriosis. Gynecol Oncol 2011; 120: 239-246.
52. McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol 2008; 61: 152-163. (Pubitemid 351218874)
53. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol 2005; 18(Suppl2): S19-S32. (Pubitemid 40188615)
54. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J Oncol 2010; 2010: 932371.
55. Callahan MJ, Crum CP, Medeiros F et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007; 25: 3985-3990. (Pubitemid 47477278)
56. Crum CP, Drapkin R, Miron A et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007; 19:3-9. (Pubitemid 46095865)
57. Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011; 42: 918-931.
58. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433-443.
59. Kurman RJ, Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008; 27:151 -160.
60. Singer G, Stohr R, Cope L et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005; 29: 218-224. (Pubitemid 40170640)
61. Stanojevic Z, Djordjevic B, Pajovic SB, Zivanov-Curlis J, Najman S. Molecular pathogenesis of borderline and invasive ovarian tumors. J BUON 2009; 14:7-18.
62. Obata K, Morland SJ, Watson RH et al. Frequent PTEN/ MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998; 58: 2095-2097. (Pubitemid 28232892)
63. Shahbazian D, Roux PP, Mieulet V et al. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 2006; 25:2781-2791. (Pubitemid 43980385)
64. Janda E, Lehmann K, Killisch I et al. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 2002; 156: 299-313. (Pubitemid 34839911)
65. Sabbah M, Emami S, Redeuilh G et al. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat 2008; 11: 123-151.
66. Ahmed AA, Etemadmoghadam D, Temple J et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010; 221: 49-56.
67. Ross JS, Yang F, Kallakury BV, Sheehan CE, Ambros RA, Muraca PJ. HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. Am J Clin Pathol 1999, 111: 311-316. (Pubitemid 29102738)
68. Cheng JQ, Godwin AK, Bellacosa A et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/ threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992; 89: 9267-9271.
69. Bellacosa A, de Feo D, Godwin AK et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995; 64: 280-285.
70. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003; 3: 895-902. (Pubitemid 37500174)
71. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-768.
72. Dick JE. Looking ahead in cancer stem cell research. Nat Biotechnol 2009; 27:44-46.
73. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111. (Pubitemid 33041634)
74. Hirschmann-Jax C, Foster AE, Wulf GG, Goodell MA, Brenner MK. A distinct "side population" of cells in human tumor cells: implications for tumor biology and therapy. Cell Cycle 2005; 4: 203-205. (Pubitemid 41365315)
75. Staud F, Pavek P. Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol 2005; 37: 720-725. (Pubitemid 40202994)
76. Magni M, Shammah S, Schiro R, Mellado W, Dalla-Favera R, Gianni AM. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 1996; 87: 1097-1103. (Pubitemid 26043537)
77. Dylla SJ, Beviglia L, Park DC et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008;3:e2428.
78. Diehn M, Cho RW, Lobo NA et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009; 458:780-783.
79. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007; 23: 675-699.
80. Todaro M, Alea MP, Di Stefano AB et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1: 389-402. (Pubitemid 47506537)
81. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760. (Pubitemid 44949604)
82. Bapat SA. Human ovarian cancer stem cells. Reproduction 2010; 140: 33-41.
83. Zhou S, Schuetz JD, Bunting KD et al. The ABC transporter BCRP1 /ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7: 1028-1034. (Pubitemid 32937383)
84. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002; 99: 507-512. (Pubitemid 34533085)
85. Diestra JE, Scheffer GL, Catala I et al. Frequent expression of the multi-drug resistance-associated protein CRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 2002; 198:213-219. (Pubitemid 35243879)
86. Hirschmann-Jax C, Foster AE, Wulf GG et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci US A 2004; 101: 14228-14233. (Pubitemid 39305058)
87. Yano S, Ito Y, Fujimoto M, Hamazaki TS, Tamaki K, Okochi H. Characterization and localization of side population cells in mouse skin. Stem Cells 2005; 23: 834-841. (Pubitemid 40791798)
88. Majka SM, Beutz MA, Hagen M, Izzo AA, Voelkel N, Helm KM. Identification of novel resident pulmonary stem cells: form and function of the lung side population. Stem Cells 2005; 23: 1073-1081. (Pubitemid 41377723)
89. Alvi AJ, Clayton H, Joshi C et al. Functional and molecular characterisation of mammary side population cells. Breast Cancer Res 2003; 5: R1-R8.
90. Nishimura F, Yoshikawa M, Kanda S et al. Potential use of embryonic stem cells for the treatment of mouse parkinsonian models: improved behavior by transplantation of in vitro differentiated dopaminergic neurons from embryonic stem cells. Stem Cells 2003; 21: 171-180. (Pubitemid 36331760)
91. Feuring-Buske M, Hogge DE. Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(-) progenitor cells from patients with acute myeloid leukemia. Blood 2001;97:3882-3889.
92. Wulf GG, Wang RY, Kuehnle I et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001; 98: 1166-1173.
93. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003; 22: 7340-7358. (Pubitemid 37487163)
94. Seigel GM, Campbell LM, Narayan M, Gonzalez-Fernandez F. Cancer stem cell characteristics in retinoblastoma. Mol Vis 2005; 11: 729-737. (Pubitemid 41410200)
95. Giangreco A, Shen H, Reynolds SD, Stripp BR. Molecularphenotype of airway side population cells. Am J Physiol Lung Cell Mol Physiol 2004; 286: L624-L630. (Pubitemid 38365044)
96. Moserle L, Indraccolo S, Ghisi M et al. The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res 2008; 68: 5658-5668.
97. Gao Q, Geng L, Kvalheim G, Gaudernack G, Suo Z. Identification of cancer stem-like side population cells in ovarian cancer cell line OVCAR-3. Ultrastruct Pathol 2009; 33: 175-181.
98. Tin AH, Miraglia S, Zanjani ED et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90: 5002-5012. (Pubitemid 28007217)
99. Miraglia S, Godfrey W, Yin AH et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997; 90: 5013-5021. (Pubitemid 28007218)
100. Miki J, Furusato B, Li H et al. Identification of putative stem cell markers, CD 133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 2007; 67: 3153-3161. (Pubitemid 46724852)
101. Olempska M, Eisenach PA, Ammerpohl O, Ungefroren H, Fandrich F, Kalthoff H. Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int 2007; 6: 92-97. (Pubitemid 46243168)
102. Yin S, Li J, Hu C et al. CD 133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007; 120: 1444-1450. (Pubitemid 46355378)
103. Rutella S, Bonanno G, Procoli A et al. Cells with characteristics of cancer stem/progenitor cells express the CD 133 antigen in human endometrial tumors. Clin Cancer Res 2009; 15: 4299-4311.
104. Friel AM, Zhang L, Curley MD et al. Epigenetic regulation of CD 133 and tumorigenicity of CD 133 positive and negative endometrial cancer cells. Reprod Biol Endocrinol 2010; 8: 147.
105. Ferrandina G, Bonanno G, Pierelli L et al. Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer 2008; 18: 506-514. (Pubitemid 351668323)
106. Ferrandina G, Martinelli E, Petrillo M et al. CD 133 antigen expression in ovarian cancer. BMC Cancer 2009; 9: 221.
107. Baba T, Convery PA, Matsumura N et al. Epigenetic regulation of CD 133 and tumorigenicity of CD 133+ ovarian cancer cells. Oncogene 2009; 28: 209-218.
108. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci 2002; 39: 527-579. (Pubitemid 35425379)
109. Krause DS, Lazarides K, von Andrian UH, Van EttenRA. Requirement for CD44 in homing and engraftment of BCR- ABL-expressing leukemic stem cells. Nat Med 2006; 12: 1175-1180. (Pubitemid 44527353)
110. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006; 12: 1167-1174. (Pubitemid 44527352)
111. Kusumbe AP, Bapat SA. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res 2009; 69: 9245-9253.
112. Saegusa M, Machida D, Hashimura M, Okayasu I. CD44 expression in benign, premalignant, and malignant ovarian neoplasms: relation to tumour development and progression. J Pathol 1999; 189: 326-337. (Pubitemid 29489216)
113. Uhl-Steidl M, Muller-Holzner E, Zeimet AG et al. Prognostic value of CD44 splice variant expression in ovarian cancer. Oncology 1995; 52: 400-406.
114. Zeimet AG, Widschwendter M, Uhl-Steidl M et al. High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer. Br J Cancer 1997; 76: 1646-651. (Pubitemid 27520596)
115. Steffensen KD, Alvero AB, Yang Y et al. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J Oncol 2011; 2011: 620523.
116. Auzenne E, Ghosh SC, Khodadadian M et al. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia 2007; 9: 479-486. (Pubitemid 46983450)
117. Akira S, Hoshino K. Myeloid differentiation factor 88-dependent and -independent pathways in toll-like receptor signaling. J Infect Dis 2003; 187(Suppl 2): S356-S363. (Pubitemid 36724509)
118. Kondoh E, Mori S, Yamaguchi T et al. Targeting slow proliferating ovarian cancer cells. Int J Cancer 2010; 126: 2448-2456.
119. Murphy SK. Targeting ovarian cancer-initiating cells. Anticancer Agents Med Chem 2010; 10: 157-163.
120. Slomiany MG, Dai L, Tolliver LB, Grass GD, Zeng Y, Toole BP. Inhibition of functional hyaluronan-CD44 interactions in CD133-positive primary human ovarian carcinoma cells by small hyaluronan oligosaccharides. Clin Cancer Res 2009; 15: 7593-7601.
121. Bhattacharya R, Kwon J, Ali B et al. Role of hedgehog signaling in ovarian cancer. Clin Cancer Res 2008; 14: 7659-7666.
122. Yauch RL, Gould SE, Scales SJ et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008; 455: 406-410.
123. Theunissen JW, de Sauvage FJ. Paracrine Hedgehog signaling in cancer. Cancer Res 2009; 69: 6007-6010.
124. Park JT, Li M, Nakayama K et al. Notch3 gene amplification in ovarian cancer. Cancer Res 2006; 66: 6312-6318.
125. Rask K, Nilsson A, Brannstrom M et al. Wnt signaling pathway in ovarian epithelial tumours: increased expression of beta-patento and GSK3beta. Br J Cancer 2006; 89: 1298-1304. (Pubitemid 37363420)
126. Sagae S, Kobayashi K, Nishioka Y et al. Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas. Jpn J Cancer Res 1999; 90: 510-515. (Pubitemid 29267704)
127. Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suarez A, Armas A. Beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999; 155: 527-536. (Pubitemid 29370402)
128. Wright K, Wilson P, Morland S et al. Beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int J Cancer 1999; 82: 625-629. (Pubitemid 29356957)
129. Zhou L, An N, Haydon RC et al. Tyrosine kinase inhibitor STI571 /Gleevec down-regulates the beta-catenin signaling activity. Cancer Lett 2003; 193: 161-170. (Pubitemid 36428898)
130. Bissell MJ, Labarge MA. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 2005; 7: 17-23. (Pubitemid 40126379)
131. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005; 7: 513-520. (Pubitemid 40799245)
132. Hamano Y, Zeisberg M, Sugimoto H et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 2003; 3: 589-601. (Pubitemid 36808653)